For research use only. Not for therapeutic Use.
Thr101 is an inhibitor (IC50=2.9 μM) of phosphomannose isomerase (PMI).PMI can compete with phosphomannose mutase 2 (PMM2) for the binding site of Man-6-P and convert mannose-6-phosphate (Man-6-P) into fructose-6-phosphate (Fru-6-P) .Thr101 only specifically inhibits PMI and not PMM2. Thr101 can be used for research of congenital disorder of glycosylation type Ia (CDG-Ia)[1].
| Catalog Number | I037263 |
| CAS Number | 727664-79-1 |
| Synonyms | 6-fluoro-2-(2-methylphenyl)-1,2-benzothiazol-3-one |
| Molecular Formula | C14H10FNOS |
| Purity | ≥95% |
| InChI | InChI=1S/C14H10FNOS/c1-9-4-2-3-5-12(9)16-14(17)11-7-6-10(15)8-13(11)18-16/h2-8H,1H3 |
| InChIKey | BUIZTXXZBDUOCR-UHFFFAOYSA-N |
| SMILES | CC1=CC=CC=C1N2C(=O)C3=C(S2)C=C(C=C3)F |
| Reference | [1]. Dahl R, et al. Potent, selective, and orally available benzoisothiazolone phosphomannose isomerase inhibitors as probes for congenital disorder of glycosylation Ia. J Med Chem. 2011 May 26;54(10):3661-8. |
